Liver Diseases  >>  grazoprevir (MK-5172)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
grazoprevir (MK-5172) / Merck (MSD)
NCT01440595 / 2011-003299-36: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Terminated
2
5
NA
Grazoprevir, MK-5172, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN), PegIntron®, SCH 054031, Ribavirin (RBV), Rebetol®, SCH 018908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/12
05/12
NCT01353911 / 2011-000759-18: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Checkmark
Apr 2014 - Apr 2014: 
Checkmark IWCPHT 2013
Jul 2013 - Jul 2013: IWCPHT 2013
Checkmark APASL 2013
More
Completed
2
368
NA
Grazoprevir, Boceprevir, Victrelis, Placebo for Grazoprevir, Placebo for Boceprevir, Peg-interferon alfa-2b, PegIntron, Peg-IFN alfa-2b, Ribavirin, Rebetol
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
01/13
03/15

Download Options